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Th  e World Health Organization has developed a single 
international standard for the information that authors of 
clinical trials must disclose [1]. Th  e informed consent 
form (original or subsequent versions if the trial protocol 
necessitates) is not among the listed items. More recent 
schemes to expand registration of clinical trials also do 
not include full disclosure of informed consent forms 
[2,3]. We strongly feel that the exclusion of informed 
consent is a serious omission in our current attempt to 
make clinical trials more transparent; we give four 
speciﬁ  c reasons in support of this view:
1. Th   e patients and the public should know whether the 
study involves a medication that has already been 
shown to be eﬀ  ective in other similar studies. Informed 
consent forms are supposed to include this information 
to help patients make an informed decision about the 
possible beneﬁ  t they may get from participating in the 
trial. Although all clinical trials should ideally be 
conducted with the goal of improving medical know-
ledge, other reasons for clinical trials, including simple 
promotion, are seen [4]. Th  ere is little scientiﬁ  c  or 
societal gain in repeating clinical trials with medica-
tions that have already shown eﬃ   cacy [5].
2. Th  ere can be considerable variation in how informed 
consent is addressed by investigators from diﬀ  erent 
cultures and socioeconomic settings, even within the 
same multinational trial [6]. Th  ese diﬀ  erences  can 
become more important and worrisome when drug 
trials are conducted in developing countries [7] where 
the investigators and sponsors might be more relaxed 
as to ethical standards of human experimentation. 
Transparency of the informed consent forms may 
facilitate the local and international surveillance of 
unethical scientiﬁ  c conduct.
3. Th  ere are examples of clinical trials that appear 
unnecessarily prolonged after the evidence is already 
available for a clear beneﬁ  cial eﬀ  ect. We had expressed 
such concern for a major drug trial in rheumatology 
some years ago [8]. In that instance, we had pointed 
out that a beneﬁ  cial  eﬀ   ect of the study drug was 
apparent at the end of the ﬁ   rst year, leading to a 
concern regarding whether patients who were invited 
to continue the trial into the second year were 
informed that there was a signiﬁ   cant chance they 
would not get the superior therapy during the second 
year. Our concerns would have been addressed right 
away had the informed consent for the extension been 
available in a clinical trials database.
4. Th   e issue of informed consent is even more important 
in trials designed to assess safety. If one takes the 
Popperian view that an honest attempt at falsiﬁ  cation 
is the correct way to test a hypothesis [9], a 
randomized clinical trial to assess safety is diﬃ   cult to 
design and conduct. A rigorous safety study includes 
an intention to bring harm. Th  e medication will be 
considered safe if the null hypothesis cannot be 
documented concern  ing the intended harm. One 
might even suggest that a societal good can hardly 
ever be justiﬁ  ed in a randomized controlled safety 
trial [10]. Th  erefore, the wording of the informed 
consent document is espe  cially important in such 
safety trials.
A recent communication addressed the issue of in-
formed consent related to such a trial in some detail [11]. 
Th   e principal investigator of this randomized controlled 
safety trial stated that he was unsure whether he was able 
to disclose the informed consent forms of this trial. How 
does one inform a patient that the scientiﬁ  c experiment 
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degree potentially do, as an endpoint?
Th   e concept of clinical trial registry has been designed 
to disseminate knowledge about clinical trials. Currently, 
brief protocol summaries, including aims, primary 
outcomes, inclusion and exclusion criteria, duration of 
the trial, and planned intervention, of all clinical trials are 
available on the internet. Concern for proprietary rights 
precludes a verbatim openness of the drug protocols at 
this time. Th   is can be understandable. What is not under-
standable is why the informed consent forms, basically 
the translation of what the protocol dictates to the patient 
level, is not part of these registries.
It is worth noting that the current practice of approving 
the clinical trial applications, including the informed 
consent forms, at institutional review boards (IRBs) does 
involve the input of the public. Th  ere is at least one 
layman member, from the local community, who is part 
of the IRB. However, this is a very limited and short-term 
public availability and thus a very limited and short-term 
transparency. What needs to be done is to make this 
transparency widespread and permanent, thus greatly 
enhancing the awareness of the public, peers, and 
patients of what is being studied.
We propose that, from now on, all clinical trial 
investigators be required to post the informed consent 
documents in public clinical trial registries. Th  us, all 
interested parties could easily review the initial informed 
consent form as given to the potential trial participants 
(or forms in case of multicenter trials due to separate 
local IRBs) and any amendments thereafter.
We appreciate that the transparency we are proposing 
might not be the answer in ﬁ  nding a solution, especially 
in the short term and in diﬀ  ering geographic locations, to 
each of the four separate issues we listed above. However, 
we strongly suggest that it will be a step in the right 
direction. For example, it simply is not practical that the 
public at large should have a say in the decision of a local 
IRB before or after each time a decision is reached for 
any one trial. On the other hand, the wide recognition 
that anyone concerned can have full access to the mode 
of conduct of a trial before, during, or after it is 
conducted will, we like to think, eventually lead to higher 
ethical standards. Our proposal is akin to the now well-
recognized ‘What would my patients or colleagues 
think?’ yardstick to improve physician-industry relations 
[12].
Since the main purpose of what we propose is 
availability upon need and since all data deposit will most 
likely be electronic, such storage would be relatively easy. 
In such a scheme, it is especially important to leave the 
older versions of the amended forms in the registry. Only 
then can a peer-reviewer or any other individual auditor 
assess whether the trial is running, has been running, or 
had been running in accordance with the best scientiﬁ  c 
and ethical conduct.
We, like others [4], are concerned about erosion of 
trust in physicians. Our relationship with the pharma-
ceutical industry, including designing and running drug 
trials, is an important component of this issue. We like to 
think that total transparency of the patients’ informed 
consent forms would provide a signiﬁ   cant step in 
restoring trust. Th   e public’s informed consent to what we 
do in a clinical trial will not be complete unless the 
patients’ informed consent document becomes public.
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